- Home
- NCV vs ABEO Comparison
NCV vs ABEO Comparison
Compare NCV & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- ABEO
- Stock Information
- Founded
- NCV 2003
- ABEO 1974
- Country
- NCV United States
- ABEO United States
- Employees
- NCV N/A
- ABEO N/A
- Industry
- NCV Finance Companies
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- ABEO Health Care
- Exchange
- NCV Nasdaq
- ABEO Nasdaq
- Market Cap
- NCV 326.0M
- ABEO 332.0M
- IPO Year
- NCV N/A
- ABEO 1980
- Fundamental
- Price
- NCV $14.75
- ABEO $6.83
- Analyst Decision
- NCV
- ABEO Strong Buy
- Analyst Count
- NCV 0
- ABEO 6
- Target Price
- NCV N/A
- ABEO $18.17
- AVG Volume (30 Days)
- NCV 405.1K
- ABEO 702.3K
- Earning Date
- NCV 01-01-0001
- ABEO 08-14-2025
- Dividend Yield
- NCV 12.48%
- ABEO N/A
- EPS Growth
- NCV N/A
- ABEO N/A
- EPS
- NCV N/A
- ABEO 0.99
- Revenue
- NCV N/A
- ABEO $400,000.00
- Revenue This Year
- NCV N/A
- ABEO N/A
- Revenue Next Year
- NCV N/A
- ABEO $339.63
- P/E Ratio
- NCV N/A
- ABEO $6.91
- Revenue Growth
- NCV N/A
- ABEO N/A
- 52 Week Low
- NCV $2.84
- ABEO $3.93
- 52 Week High
- NCV $3.59
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- NCV 66.05
- ABEO 52.71
- Support Level
- NCV $14.27
- ABEO $6.70
- Resistance Level
- NCV $14.78
- ABEO $7.15
- Average True Range (ATR)
- NCV 0.14
- ABEO 0.31
- MACD
- NCV 0.01
- ABEO -0.02
- Stochastic Oscillator
- NCV 90.57
- ABEO 46.62
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.